Alliance Reports Results from First Randomized Trial of a Radiopharmaceutical in Kidney Cancer
RadiCaL study results show adding bone-targeting radium-223 to cabozantinib does not improve symptomatic skeletal-related events, highlighting the value of current standard treatments to optimize bone health for patients with bone metastases. Results from the Alliance for Clinical Trials in Oncology’s Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney…